Recent Updates
Recently added Catalysts

Chronic Spontaneous Urticaria: one US-listed biotech with a clinical-stage programme

Immunology & InflammationUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$3.1Buniverse median $1.20B
Allocated capital$1.0B$3.1B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank149/299crowding rank 163

Chronic Spontaneous Urticaria is uncontested. Celldex Therapeutics (CLDX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Barzolvolimab in phase 3.

There is no public comparable to price it against. CLDX spreads its $3.1B market cap across 3 indications, so $1.0B of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$1.0B of allocated capital sits in Chronic Spontaneous Urticaria, ranking it 149th of 299 indications by the money committed to it.

Companies developing drugs for Chronic Spontaneous Urticaria 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CLDXCelldex TherapeuticsBarzolvolimabPhase 33$3.1BNo3 31 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Chronic Spontaneous Urticaria counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Chronic Spontaneous Urticaria has one competitor and a median of $3.1B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Autoimmune Pulmonary Alveolar Proteinosis1 company · $1.1B · median $1.1BUncontestedPeanut Allergy1 company · $861M · median $861MUncontestedPruritus2 companies · $1.2B · median $1.6BConcentrated betEosinophilic Esophagitis2 companies · $1.2B · median $610MOrphan cornerCeliac Disease1 company · $788M · median $1.6BUncontestedModerate to Severe Atopic Dermatitis1 company · $1.3B · median $2.6BUncontestedChronic Granulomatous Disease1 company · $673M · median $673MUncontestedAcne1 company · $673M · median $673MUncontested

Chronic Spontaneous Urticaria pipeline questions

Which biotech companies are developing drugs for Chronic Spontaneous Urticaria?

Celldex Therapeutics (CLDX, Barzolvolimab, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Chronic Spontaneous Urticaria.

How advanced is the Chronic Spontaneous Urticaria pipeline?

Of the 1 clinical-stage programme in Chronic Spontaneous Urticaria, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Chronic Spontaneous Urticaria?

No. CLDX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Chronic Spontaneous Urticaria, which is why the indication is classified as uncontested.

When is the next Chronic Spontaneous Urticaria catalyst?

The next dated catalyst in Chronic Spontaneous Urticaria is CLDX on 31 Oct 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map